series-c-plus
Stage
2
Investors
About
Cellusion develops regenerative medicine technologies using iPS cell-derived corneal endothelial cell substitutes to treat corneal endothelial diseases, aiming to address donor shortages and improve transplantation procedures globally.
Explore Cellusion's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.